What Happened?
South San Francisco, CA-based Reset-Therapeutics Appointed Ross Bersot as Chief Executive Officer
About the Company
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body`s network of internal molecular clocks. The circadian system synchronizes behavioral and physiological processes, including sleep, metabolism, feeding, blood pressure and hormone secretion with the environmental cycles of light, activity and nutrient status. Disruption of normal circadian rhythms is associated with many diseases, including central nervous system, cardiovascular and metabolic disorders, immune system dysfunction and cancer. Novel therapies that reset the body’s biological clocks have the potential to benefit very large and diverse patient populations
About the Person
Ross Bersot, CFA is the President and CEO of Reset Therapeutics. Mr. Bersot founded Reset Therapeutics in 2008 with Dr. Ronald Evans (Salk Institute) and Drs. Joseph Takahashi and Masashi Yanagisawa (University of Texas Southwestern Medical Center). Previously, Mr. Bersot was a Managing Director of Bay City Capital, where he focused on investment opportunities in visionary biopharmaceutical and enabling technology companies. He is a member of the board of directors of Reset Therapeutics and an observer on the board of Epizyme, Inc. Mr. Bersot also serves on the board of directors of Wild4Life, a nonprofit that provides essential health services to rural communities in remote areas of Zimbabwe and other African nations via partnerships with local employers and government-related organizations. He is also the Regional Chairman of the Northern California Volunteer Committee for the UCLA Fund Chancellor’s Society. Mr. Bersot received a B.A. in Economics from the University of California, Los Angeles.
Info Source
Press Release
Short Profile